FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Jun Yan, Qingnan Zhao, Konrad Gabrusiewicz, Ling-Yuan Kong, Xueqing Xia, Jian Wang, Martina Ott, Jingda Xu, R. Eric Davis, Longfei Huo, Ganesh Rao, Shao-Cong Sun, Stephanie S. Watowich, Amy B. Heimberger () and Shulin Li ()
Additional contact information
Jun Yan: Capital Medical University
Qingnan Zhao: The University of Texas MD Anderson Cancer Center
Konrad Gabrusiewicz: The University of Texas MD Anderson Cancer Center
Ling-Yuan Kong: The University of Texas MD Anderson Cancer Center
Xueqing Xia: The University of Texas MD Anderson Cancer Center
Jian Wang: The University of Texas MD Anderson Cancer Center
Martina Ott: The University of Texas MD Anderson Cancer Center
Jingda Xu: The University of Texas MD Anderson Cancer Center
R. Eric Davis: The University of Texas MD Anderson Cancer Center
Longfei Huo: The University of Texas MD Anderson Cancer Center
Ganesh Rao: The University of Texas MD Anderson Cancer Center
Shao-Cong Sun: The University of Texas MD Anderson Cancer Center
Stephanie S. Watowich: The University of Texas MD Anderson Cancer Center
Amy B. Heimberger: The University of Texas MD Anderson Cancer Center
Shulin Li: The University of Texas MD Anderson Cancer Center

Nature Communications, 2019, vol. 10, issue 1, 1-15

Abstract: Abstract Few studies implicate immunoregulatory gene expression in tumor cells in arbitrating brain tumor progression. Here we show that fibrinogen-like protein 2 (FGL2) is highly expressed in glioma stem cells and primary glioblastoma (GBM) cells. FGL2 knockout in tumor cells did not affect tumor-cell proliferation in vitro or tumor progression in immunodeficient mice but completely impaired GBM progression in immune-competent mice. This impairment was reversed in mice with a defect in dendritic cells (DCs) or CD103+ DC differentiation in the brain and in tumor-draining lymph nodes. The presence of FGL2 in tumor cells inhibited granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced CD103+ DC differentiation by suppressing NF-κB, STAT1/5, and p38 activation. These findings are relevant to GBM patients because a low level of FGL2 expression with concurrent high GM-CSF expression is associated with higher CD8B expression and longer survival. These data provide a rationale for therapeutic inhibition of FGL2 in brain tumors.

Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-08271-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-018-08271-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-08271-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().